Australian researchers have discovered a new way to target an aggressive childhood cancer, neuroblastoma, one of the most common and dangerous cancers in young children.
Mar 26, 2021
0
433
Researchers have discovered how the modified natural compound dextran-catechin disrupts formation of blood vessels that fuel growth in the childhood cancer neuroblastoma.
Aug 10, 2017
0
869
The anti-depressant drug Prozac could be used to tackle one of the deadliest childhood tumours and possibly other types of cancer, scientists said.
Jan 10, 2020
1
3372
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...
Jun 18, 2018
0
31
Immunotherapies are changing the outlook for many cancer patients.
May 3, 2017
0
345
Neuroblastoma is a devastating solid tumor of childhood and emerges in the sympathetic nervous system while many kids who develop it are still toddlers.
Neuroblastoma accounts for 15% of total childhood cancer deaths. The survival rate of high-risk neuroblastoma patients is 50%.
Jul 26, 2019
0
2278
Researchers at Lund University in Sweden have identified one of the reasons why the childhood cancer neuroblastoma becomes resistant to chemotherapy. The findings are significant for how future treatments should be designed. ...
Nov 11, 2022
0
62
A new study reveals that pediatric neuroblastoma patients are at elevated risk for long-term psychological impairment. In addition, those who experience such impairment as they get older tend to require special education ...
Jun 11, 2018
0
179
Pediatric oncologists from The Children's Hospital of Philadelphia (CHOP) have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma.
Jan 6, 2016
0
365
Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 new cases per year in the US. Close to 50 percent of neuroblastoma cases occur in children younger than two years old. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system or SNS. It most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.
Neuroblastoma is one of the few human malignancies known to demonstrate spontaneous regression from an undifferentiated state to a completely benign cellular appearance.
A disease exhibiting extreme heterogeneity, neuroblastoma is stratified into three risk categories: low, intermediate, and high risk. Low-risk disease is most common in infants and highly curable with observation only or surgery, whereas high-risk disease is difficult to cure even with the most intensive multi-modal therapies available.
Note: Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. However, since it is not a sympathetic nervous system malignancy it is a distinct clinical entity and is not to be confused with neuroblastoma.
This text uses material from Wikipedia, licensed under CC BY-SA
